Inova

Quick links to important sections

Inova

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inova

Property Description
Active Ingredient Benzoyl Peroxide (BPO)
Form Topical preparation (lotion, gel, or cream)
Pharmacological Class Topical Acne Agent / Antiseptic
General Purpose Management of Acne Vulgaris
Origin Synthetic compound

What Type of Topical Agent is Inova?

Inova is a topical treatment classified as a Topical Acne Agent or Antiseptic. The medicine is defined by its core active ingredient, Benzoyl Peroxide (BPO), a synthetic chemical compound. This classification establishes Inova as a localized, non-systemic intervention, distinguishing it from medications that are taken orally and absorbed throughout the body. The fundamental role of BPO for acne management is clinically recognized, characterized by its oxidizing properties which make it an effective topical agent for acne treatment.

Composition and Product Variations

The composition of Inova is centered on Benzoyl Peroxide, which provides the product's primary therapeutic action. This medicine is available as a topical preparation in several dosage forms, including a cleansing lotion, gel, or cream base, and is often supplied as a treatment kit. This kit format is a key differentiating feature, often bundling the BPO treatment with complimentary cleansing products. While the base product is a single-ingredient therapy, certain branded variations are combination products that incorporate a secondary active ingredient, Salicylic Acid. This combination approach is based on the principle that the combined use of Benzoyl Peroxide with a keratolytic agent provides enhanced efficacy for clearing inflammatory lesions.

General Therapeutic Purpose

The overall purpose of Inova is to help manage and control the superficial manifestations of Acne Vulgaris. Its function is primarily driven by the bactericidal action of Benzoyl Peroxide, which works to reduce the population of Cutibacterium acnes, a key factor in the development of inflammatory acne. By also providing mild drying and pore-clearing effects, the medicine directly addresses both the bacterial proliferation and the presence of obstructed hair follicles, which is how it aids in mitigating and controlling acne symptoms.

Regulatory References

  1. Benzoyl Peroxide
  2. Topical Acne Agent
  3. Acne Vulgaris
  4. MedlinePlus
  5. Salicylic Acid

What side effects are possible with Inova?

Possible Side Effects and Safety Information

The official safety profile of Inova (Benzoyl Peroxide) is predominantly characterized by localized skin reactions, which are classified by regulatory agencies according to frequency.


Adverse Reaction Classification

Frequency Category Documented Adverse Reactions (Skin and Subcutaneous Tissue Disorders)
Very Common (ge 1/10) Erythema (redness), Desquamation (peeling/flaking), Dry skin
Common (ge 1/100 to < 1/10) Burning sensation, Pruritus (itching), Irritation, Pain at the application site

These effects are frequently more prominent at the beginning of treatment and are documented to decrease with continued, regular use. The majority of reactions fall under the Skin and subcutaneous tissue disorders System-Organ Class, reflecting the medicine's topical action.


Serious Safety Considerations

The regulatory safety profile includes the rare, but serious, risk of Immune system disorders (hypersensitivity reactions). Officially documented serious adverse reactions include Anaphylaxis and Angioedema (swelling of the face, lips, or throat). These require immediate cessation of use if they occur.

Safety labeling also defines high-level constraints for use. The medicine is contraindicated in individuals with a known history of hypersensitivity to Benzoyl Peroxide. Furthermore, to prevent severe local irritation, contact with the eyes, mouth, nose, and other mucous membranes must be strictly avoided. Use in children under 12 years of age is generally not recommended or requires professional oversight, as stated in some national monographs.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents establish two distinct types of overexposure for this topical medication, which contains Benzoyl Peroxide (BPO): severe local effects from excessive application and acute systemic hypersensitivity.

Documented Overdose Manifestations

Classification Manifestations and Outcomes
Local Overexposure Severe local irritation, including pronounced redness (erythema), scaling (exfoliation), localized swelling, or blistering at the application site.
Systemic Hypersensitivity Signs of a serious allergic reaction: swelling of the face, lips, or tongue, throat tightness, difficulty breathing, wheezing, or feeling faint (syncope/collapse).

Required Emergency Actions

Urgent medical help is required immediately if signs of serious systemic hypersensitivity are present. These signs, such as throat tightness or collapse, are documented triggers for seeking emergency services. The user must stop using the product immediately upon the onset of such symptoms.

Management for excessive topical application that results in severe local irritation is defined as discontinuing use until the skin recovers, followed by the institution of appropriate symptomatic therapy. In the event of accidental ingestion, regulatory information advises initiating symptomatic and supportive management. Regulatory labeling specifies that no specific antidote is known.

Therapeutic Uses of Inova

What Inova Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed for managing acne vulgaris. It is commonly used in conditions presenting with significant symptomatic burden, such as persistent breakouts involving inflammatory lesions, papules, pustules, and non-inflammatory blackheads and whiteheads. It is relevant when symptoms create noticeable physiological strain and when supportive symptom management is appropriate.

The medication contributes to easing the overall symptom load. Applied in clinical settings that involve acute or unstable symptom patterns, this may assist with managing symptoms that interfere with daily comfort. It also supports the management of the visible signs of irritation, which may assist with maintaining functional stability and general comfort.

“This supportive approach may assist patients with maintaining functional stability when symptoms fluctuate.”


Quick Fact: Symptomatic Support for Acne

Inova is commonly used when short-term symptomatic assistance is needed to help ease localized discomfort and the visible manifestations of an acne episode.

Eligibility and Restrictions for Use

Inova (inavolisib) is a targeted treatment for adult patients with specific characteristics of locally advanced or metastatic breast cancer. Its use is strictly defined by regulatory agencies such as the FDA and EMA.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adult patients with Hormone Receptor (HR)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer.
  • Tumors must harbor a PIK3CA mutation, confirmed by an approved test.
  • The cancer must be endocrine-resistant, meaning it recurred or progressed on or after completing prior endocrine therapy.
  • It must be used only in combination with palbociclib and fulvestrant.
  • Pre/perimenopausal women and men must also be treated with a Luteinising Hormone-Releasing Hormone (LHRH) agonist.

Populations for whom use is contraindicated:

  • Individuals with a known hypersensitivity to inavolisib or any of its excipients.

Age-related and Condition-specific Eligibility Rules:

  • Safety and efficacy have not been established in children or adolescents (under 18 years of age).
  • Use is not established or not recommended for patients with severe renal impairment or moderate to severe hepatic impairment. A reduced starting dose is required for patients with moderate renal impairment.
  • Pregnancy/Lactation: Use is not recommended during pregnancy due to the risk of fetal harm; women should be advised not to breastfeed during therapy and for one week after the last dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Inova (Benzoyl Peroxide topical) has an interaction profile characterized by localized topical effects rather than systemic interactions. Due to the drug’s low percutaneous absorption and rapid local metabolism, formal systemic pharmacokinetic interactions with orally administered medications are not documented in regulatory labeling.

Officially documented interaction risks fall into two main classifications: cumulative irritancy and chemical incompatibility.

Cumulative Irritancy

Co-administration with other topical acne agents, such as products containing Salicylic Acid, sulfur, or resorcinol, is documented to increase the likelihood of excessive dryness, peeling, or localized irritation. This additive drying effect also applies to the concurrent use of topical products that contain high concentrations of alcohol or astringents.

Chemical Incompatibility and Efficacy Reduction

Regulatory documentation notes that Inova may reduce the effectiveness of other medicines, specifically topical Tretinoin and Isotretinoin, due to the drug's oxidative properties. This interaction requires a mandatory restriction on simultaneous application, with the products typically applied at separate times of the day.

Furthermore, an incompatibility exists with topical Dapsone and sulfonamide-containing products, where co-application may result in a temporary yellow or orange discoloration of the skin and facial hair. Avoiding simultaneous use may prevent this staining.

Mechanism of Action

Targeted Bactericidal Oxidation and Inflammatory Signaling

The core mechanism of Benzoyl Peroxide (BPO) involves the rapid generation of Benzoyloxy free radicals within the hair follicle, which nonspecifically oxidize and disrupt the proteins and lipids of Cutibacterium acnes. This direct bactericidal action leads to a reduction in the bacterial load and associated local inflammatory signaling.


Dual Keratolysis and Follicular Clearance

The medicine acts as a comedolytic agent by influencing the process of keratinocyte desquamation (shedding). Salicylic Acid (if present) solubilizes the intercellular cement holding follicular skin cells together, while BPO assists in breaking down the keratinous material. This complementary mechanism accelerates the clearance of follicular impactions and influences the abnormal cell turnover that leads to obstruction.


Mechanistic Synergy and Constraint

When combined, the keratolytic effect influences the bactericidal action by structurally clearing the pore, which facilitates the access of BPO to its bacterial targets. While the mechanism effectively influences the bacterial and structural pathways, its action is confined to the peripheral level and does not directly modulate the systemic hormonal pathways.

Dosage and Administration Information

Inova is an external medication that follows a standardized administration protocol. The Route of administration is strictly cutaneous (topical), meaning it is applied directly to the affected skin and is not approved for internal use, including the eyes or mouth.


The Dosing schedule is typically once or twice daily, utilizing concentrations that range from 2.5% to 10% Benzoyl Peroxide. It is often suggested to initiate treatment with a lower strength to establish skin tolerance. Application involves spreading a thin film over the affected area, after the skin has been cleaned and fully dried. For optimal use, hands must be washed immediately after application to prevent the product from bleaching fabrics or hair.


The usage protocol includes specific procedural boundaries. Application must avoid mucous membranes and any broken or abraded skin. If noticeable irritation, such as excessive peeling or dryness, occurs, the frequency of use should be reduced. In terms of Course duration, patients typically observe initial clinical changes within the first one to four weeks. For most single-agent formulations, use in children below 12 years of age is not established, defining a key population-specific instruction. Applying more product or increasing the frequency beyond the labeled amount will not enhance efficacy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Inova

Evidence for the Management of Acne Vulgaris Symptoms

The research foundation for Inova (Benzoyl Peroxide) focuses on its application in studies that explore the patterns related to inflammatory and non-inflammatory acne lesions. The core evidence comes from Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that aggregate data. These RCTs were a principal study design used in research that monitored outcomes over defined time intervals.

Studies monitored outcomes related to the severity of the condition. Researchers primarily focused on quantifying visible lesions, measuring changes in the total count of both inflammatory and non-inflammatory lesions. Research also examined symptom patterns monitored by overall skin severity scales. These study populations generally included adolescents and adults with mild to moderate acne conditions.

In the observed populations, studies reported patterns of change in lesion counts when assessments of the Benzoyl Peroxide preparations were compared against inactive controls. Studies monitored how symptoms evolved in the observed populations, and research highlights changes measured during the short-term study periods. This body of research adds to the existing body of scientific knowledge and does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Assessment of Long-Term Use and Durability of Effect

The research exploring short-term symptom changes typically conducted follow-up assessments over defined time intervals, generally extending up to 12 to 16 weeks. This short-term research provides insight into the initial symptom patterns observed during periods of increased symptom activity.

However, long-term effects are not fully established. The majority of key RCTs have follow-up durations that were limited, primarily focusing on the intermediate-term response (up to three or four months). Research for long-term outcomes, such as use over six months or more for maintenance therapy, remains insufficient in many established trials. Because evidence is limited, the durability of the observed findings over extended periods is not well characterized in the current research record.

Research Evidence Across Different Populations

Inova was evaluated in studies examining patient-reported experiences and physical outcomes in a broad group of adolescents and adults with varying symptom burdens. The results apply only to the populations studied, which primarily covered mild to moderate disease severity.

Research for certain groups remains insufficient. For instance, evidence is limited regarding the use of Benzoyl Peroxide in older adults or in individuals with complex, co-occurring skin or systemic conditions. Research has explored this medicine in settings with varying symptom burdens, but comparative evidence is lacking or inconsistent for many specific subgroups, meaning that certainty remains low for outcomes outside of the typical study population.

Frequently Asked Questions (FAQ)

Common questions about Inova (FAQ)


Q: Is Inova a generic medication or a brand-name medication?

A: Inova's active ingredient, Benzoyl Peroxide, is officially recognized by the FDA as a Generally Recognized As Safe and Effective (GRASE) substance for topical acne treatment. This classification means the ingredient is widely available in many different products. As a result, the medicine may be found in both a generic form and in various branded formulations.


Q: How is Inova different from other similar treatments in the same drug class?

A: According to regulatory descriptions, Inova (Benzoyl Peroxide) works through a dual mechanism. Its primary action is bactericidal, meaning it directly kills the bacteria associated with acne using an oxidizing effect. This unique mode of action, described in regulatory documentation, is a key difference between BPO and agents that rely only on exfoliation or antibiotic properties.


Q: Is Inova a medication that requires a special prescription or monitoring program?

A: Products containing Benzoyl Peroxide are typically available for purchase Over-the-Counter (OTC) at concentrations ranging from 2.5% to 10%. Official guidance states that some combination products or higher-strength formulations may require a prescription. Decisions regarding specific oversight would be determined by a healthcare provider based on the product being used.


Q: Can I take Inova if I have a pre-existing liver or kidney condition?

A: Official safety data focuses on the minimal amount of the medicine absorbed by the body. Because topical Benzoyl Peroxide has low absorption through the skin and is quickly broken down, systemic effects on the liver or kidneys are generally not documented in regulatory labeling.


Q: Were different populations (like different ethnic groups) included in the research for Inova?

A: Regulatory notes on adverse event reporting acknowledge differences in patient skin types. For instance, official product labeling has included cautionary notes that redness (erythema), a documented side effect, may be less visible or apparent on certain darker skin tones.


Q: What does the official documentation say about the maximum period a person can safely use Inova?

A: Official regulatory documents indicate that the main clinical trials for this medicine observed safety and effectiveness over a defined, short-term period, often up to 12 weeks. Therefore, official documentation indicates that evidence regarding the durability of the findings over extended periods is limited.


Q: Does taking Inova at a specific time of day (morning vs. evening) affect its efficacy?

A: While the general dosing is described as once or twice daily, specific official product information may instruct application to occur once daily in the evening. Official documentation indicates that specific timing may be instructed to minimize potential incompatibilities with other daytime topical medicines or to enhance tolerability.


Q: Are there any specific lifestyle changes that are recommended while on Inova?

A: Official warnings caution against sun exposure while using the medicine, as it can increase skin sensitivity to sunlight. For sun exposure that cannot be avoided, the use of protective measures like sunscreen and clothing is advised in the product labeling.


Q: How is the dosage of Inova determined, and does it change based on the condition being treated?

A: Official guidelines follow the principle of initiating use with a lower strength formulation to establish skin tolerance. The dose range (concentration and frequency) is generally selected based on the approved indications and the individual's local skin response.


Q: Can Inova be crushed or split if a patient has trouble swallowing pills?

A: Since this medicine is a topical preparation (gel, cream, or lotion) intended only for application to the skin, it is not an oral tablet. Therefore, instructions for crushing or splitting oral medications are not relevant to its use.


Q: Is it necessary to take Inova with a full meal, or can it be taken on an empty stomach?

A: Instructions about taking a medicine with or without food are relevant only for drugs intended for internal use. As Inova is for topical use only (applied to the skin), these directions do not apply to this preparation.


Q: What percentage of patients in studies experienced a major benefit from Inova?

A: Studies summarized in the regulatory documentation primarily report changes in specific measures, such as lesion counts and overall severity scores. While official documents do not provide a generalized percentage of patients who experienced a 'major benefit,' the specific efficacy results from controlled clinical trials, including the observed patterns of change in lesions, are available in the Clinical Studies section of the full product information.


Q: What are the key safety points about Inova that patients commonly misunderstand?

A: Official patient information highlights several important safety points for use. These include the requirement to minimize sun exposure and the necessity of preventing contact with the eyes, mouth, and other mucous membranes. The safety summary highlights the importance of recognizing the difference between common local skin irritation and the signs of a rare, serious allergic reaction.


Q: How long after stopping Inova will the substance be completely out of my system?

A: Regulatory information indicates that topical Benzoyl Peroxide is characterized by low systemic absorption. The minimal amount that does enter the body is metabolized to benzoic acid, which is then eliminated relatively quickly through the urine, according to pharmacokinetic data.


Q: Does Inova have an official patient medication guide or information leaflet?

A: Yes, for prescription products containing the active ingredient, official regulatory labeling includes a section dedicated to Patient Counseling Information. This document, often referred to as a leaflet or guide, is intended to communicate essential safety points, instructions for use, and potential risks to the patient.


Q: Is a headache a reported side effect of Inova, and is it a temporary issue?

A: Headache is not listed among the common or very common local skin reactions documented in the medicine's safety profile. Official safety data mentions that symptoms like dizziness or feeling faint are rare occurrences that have been associated with a potential severe systemic allergic reaction to the medication.


Q: What kind of supplements or herbal products are known to interact with Inova?

A: Regulatory documents indicate that no formal studies have been conducted to assess drug-drug interactions between topical Benzoyl Peroxide and oral supplements or herbal products. Because of the medicine's low systemic absorption, official sources consider the potential for systemic interactions with oral supplements to be unlikely.


Q: Is it normal to feel slightly dizzy or tired when first starting Inova?

A: Feeling slightly dizzy or tired is not documented as a common expected reaction to starting the medicine. Official safety information does list dizziness as a potential symptom of a rare, but serious, systemic allergic reaction.


Q: If I have a history of allergies to other medicines, am I more likely to react to Inova?

A: Regulatory labeling explicitly states that the medicine is contraindicated (must not be used) in anyone with a known hypersensitivity to Benzoyl Peroxide. While a history of allergies to other medications may contribute to an individual’s overall allergy risk, official documents do not explicitly state it as a contraindication for Inova itself.


Q: What is the difference between the 'on-label' use and other uses mentioned by patients online?

A: Official regulatory approval defines the only approved ('on-label') use for this medicine as the topical treatment of acne vulgaris. Any discussions of using the medicine for other conditions are considered outside of the intended use supported by the regulatory agency's review of the evidence.


Q: Is there any information about Inova's impact on fertility?

A: According to nonclinical toxicology reports, studies in animals found no apparent effect on male or female fertility from the active ingredient. Official regulatory documents indicate that specific studies on human fertility have not been conducted for the topical preparation.


Q: Why is Inova prescribed for different, seemingly unrelated conditions?

A: This confusion arises because the name 'Inova' is associated with two different active ingredients intended for two distinct conditions. The topical product containing Benzoyl Peroxide is approved for acne, while a different medicine called Inavolisib is approved for a specific type of breast cancer. The approved use is determined by the specific active ingredient and product formulation, as documented in the regulatory approval.


Q: How does the drug approval process for Inova affect the information available to the public?

A: The public information available for Inova's active ingredient is affected by its regulatory status. The FDA classified Benzoyl Peroxide as GRASE (Generally Recognized As Safe and Effective) for Over-the-Counter (OTC) use, which means its approved safety and usage information is contained within the public OTC Drug Monograph and related Final Rules.

How should Inova be stored and disposed of?

How to Store and Dispose of Inova?

Storage Component Official Requirement
Temperature Store at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F), with permitted excursions.
Protection Keep the product in its original container and closure system to protect it from excessive heat, light, and moisture.
Handling & Stability Do not use the medication after the expiration date printed on the container. For multi-dose forms, stability after the initial container entry is typically limited to a specific in-use period, such as 28 days.
Child Safety The medication must be kept out of the sight and reach of children to prevent accidental ingestion.
Disposal Unused or expired doses should be disposed of promptly and safely, often by using an authorized drug take-back program or collection site. If no program is available, follow guidance for mixing the product with an undesirable substance before sealing and discarding it in household trash, per established regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inova found in:

A-Z Index: